Biodexa (BDRX) - Price to Earnings Ratio

Corporate emblem and logo of Biodexa (BDRX)

Biodexa Pharmaceuticals (BDRX) possesses significant pricing power due to its unique methods for the targeted delivery of chemotherapeutic agents into brain tumors. This price chart demonstrates the -369.50 metric. The company's UK center focuses on the treatment of orphan diseases and oncology, while its laboratories operate according to a strict plan, utilizing flawless equipment to produce therapeutic batches.

BDRX Biodexa Pharmaceuticals: P/E Multiple in the range 04/28/2023 - 11/14/2026

Analytical breakdowns for Biodexa Pharmaceuticals

- price and consensus price forecast:
Stock Price Biodexa Pharma|BDRX - Analyst Consensus Forecast
- market capitalization indicators:
Market Valuation Biodexa Pharmaceuticals PLC|BDRX - Real Price to Acquire Entire Company
- balance sheet equity data:
Net Asset Value per Share Biodexa Pharmaceuticals|BDRX - Book Capitalization|Market Value to Book Value Ratio biodexapharma.com|BDRX - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Biodexa Pharmaceuticals|BDRX - Long-Term Debt to Equity|Current Liabilities to Capital Biodexa Pharma|BDRX - Company Aggregate Debts|Debt to Book Value Ratio Biodexa Pharmaceuticals PLC|BDRX - Company Long-Term Debts|Short-Term Debt Biodexa Pharmaceuticals|Immediate Liquidity Ratio biodexapharma.com
- business earnings and investment ratios data:
BDRX - Net Profit|Projected Future Earnings Biodexa Pharmaceuticals|BDRX - Price to Earnings Ratio|Future Price to Earnings Multiple Biodexa Pharma|BDRX - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Biodexa Pharmaceuticals PLC|BDRX - Operating profit EBITDA|Earnings per share for the trailing year Biodexa Pharmaceuticals|BDRX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth biodexapharma.com|BDRX - Earnings per share growth in current year|Expected earnings per share trend next year Biodexa Pharmaceuticals
- company sales and revenue statistics:
BDRX - Company Revenue|Company Future Sales Volume Biodexa Pharma|BDRX - P/S Multiple|Forward P/S Multiple Biodexa Pharmaceuticals PLC
Summary company analysis:biodexapharma.com BDRX
Manufactured product of Biodexa Pharmaceuticals PLC

Assessing the reliability of equity assets begins with analyzing the ratio of market capitalization to net income. This coefficient measures the cost of one dollar of current earnings, determining the extent of the premium paid for future growth. For Biodexa Pharmaceuticals (BDRX), with its unique brain drug delivery systems, such a metric reflects expectations of inelastic demand. An investor must weigh the company's potential pricing power against its current P/E ratio. The dynamics of this indicator help determine the balance point between bankruptcy risk and the innovation premium.

Key competitors

P/E Multiple CVS Corp|P/E Multiple MCK|Price to Earnings Ratio Cencora Inc COR|Cardinal Health Corp - Price to Earnings Ratio|Henry Schein Dental (HSIC) - Market Cap to Earnings|Prestige Consumer Healthcare - P/E Multiple|WGRX: Price to Earnings Ratio|YI: P/E Multiple|RDGT - Business Payback Period|Price to Earnings Ratio Universe Pharmacy|Market Cap to Earnings HK Pharma Digital HKPD|P/E Multiple BIMI|jiuzhou-drugstore.com - Price to Earnings Multiple|P/E Multiple WBA (Walgreens Boots Alliance, Inc.)